Interline Therapeutics Raises $92M in Funding

Interline Therapeutics, a San Francisco, CA-based drug discovery company, raised $92M in funding.

The round was led by Foresite Capital and ARCH Venture Partners.

The company intends to use the funds to expand the research platform and advance six preclinical therapeutic programs.

Co-founded by CEO Zachary Sweeney, Interline Therapeutics is a Foresite Labs incubated company that focuses on systematically elucidating protein communities to define molecular mechanisms of disease.

The company uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities. Interline Therapeutics is leveraging recent advancements in these technologies, as well as collaborations with academic groups, to develop a precision medicine platform focused on three essential areas:

  • Genomics: Prioritize genetic variants that drive disease by altering protein communities
  • Communities: Identify the specific molecular mechanisms through which these variants change protein community dynamics, enabled by the application of machine learning
  • Modulators: Discover and characterize drugs that reshape these communities

The discovery platform will allow the company to identify new medicines targeting genetically validated signaling pathways and ensure that drug candidates comprehensively correct dysfunctional disease networks.

The team includes Nick Galli, Chief Operating Officer, Don Kirkpatrick, Chief Technology Officer, Mario Cardozo, Vice President Computational Chemistry and Cheminformatics, Anj Saha, Vice President Discovery Pharmacology and David Tully, Vice President Medicinal Chemistry.

The company will continue to collaborate with Foresite Labs in the fields of data science and genomics. Interline also launches with foundational collaborations with University of California San Francisco and Memorial Sloan Kettering Cancer Center, as well as an internationally recognized team of founding scientific advisors, including:

  • John Chodera, PhD, Associate Member and Laboratory Director, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
  • Wade Harper, PhD, Chairman and Bert and Natalie Vallee Professor of Molecular Pathology and Cell Biology, Harvard Medical School
  • Nevan J. Krogan, PhD, Professor, Cellular and Molecular Pharmacology, UCSF, Director, Quantitative Biosciences Institutes, and Senior Investigator, Gladstone Institutes
  • Brenda Schulman, PhD, Director, Molecular Machines and Signaling, Max Planck Institute of Biochemistry
  • Mike Varney, PhD, Former Executive Vice President Research and Early Development of Genentech.